#1 Clinical Trials Search in Europe

Concizumab

This article explores the use of Concizumab, a novel drug being studied in clinical trials for the treatment of hemophilia A and B, with and without inhibitors. Concizumab is showing promise as a prophylactic treatment to prevent bleeding episodes in people with these blood clotting disorders.

Table of Contents

What is Concizumab?

Concizumab is a new medicine being studied for the treatment of hemophilia. It is also known by the brand name Alhemo[1]. Concizumab is a type of drug called a monoclonal antibody, which is a laboratory-made protein that can bind to specific targets in the body[2].

How Does Concizumab Work?

Concizumab works by targeting a protein in the blood called Tissue Factor Pathway Inhibitor (TFPI). TFPI normally helps prevent excessive blood clotting. In people with hemophilia, blocking TFPI can help improve blood clotting and reduce bleeding[3].

What Conditions Does Concizumab Treat?

Concizumab is being studied for the treatment of several types of hemophilia, including:

  • Hemophilia A with inhibitors: A genetic bleeding disorder where the body lacks a blood clotting factor called Factor VIII, and has developed antibodies that interfere with treatment[2]
  • Hemophilia B with inhibitors: A genetic bleeding disorder where the body lacks a blood clotting factor called Factor IX, and has developed antibodies that interfere with treatment[2]
  • Hemophilia A without inhibitors: The more common form of hemophilia A, where the body lacks Factor VIII but has not developed inhibitors[4]
  • Hemophilia B without inhibitors: The more common form of hemophilia B, where the body lacks Factor IX but has not developed inhibitors[4]

How is Concizumab Administered?

Concizumab is given as a daily injection under the skin (subcutaneous injection). Patients or their caregivers can learn to administer the medication at home using a special device called a pen-injector[2]. The dose may be adjusted based on individual patient needs and response to treatment.

Clinical Trials and Effectiveness

Several clinical trials have been conducted to evaluate the safety and effectiveness of concizumab. These studies have shown promising results in preventing bleeding episodes in people with hemophilia[3]. Some key findings include:

  • Reduction in the number of bleeding episodes compared to on-demand treatment[5]
  • Effectiveness in treating both spontaneous and traumatic bleeding episodes[3]
  • Potential to prevent bleeding in target joints (joints that frequently bleed in hemophilia patients)[5]

Potential Side Effects

As with any medication, concizumab may cause side effects. Researchers are closely monitoring for potential adverse events during clinical trials. Some of the side effects being studied include:

  • Thromboembolic events: These are blood clots that can potentially form in blood vessels[4]
  • Hypersensitivity reactions: These are allergic-type reactions to the medication[4]
  • Injection site reactions: These are reactions that occur at the location where the medication is injected[4]
  • Development of antibodies: The body may develop antibodies against concizumab, which could potentially affect its effectiveness[4]

It’s important to note that the full safety profile of concizumab is still being established through ongoing clinical trials.

Ongoing Research

Concizumab is still undergoing extensive research to fully understand its long-term effectiveness and safety. Several clinical trials are currently in progress or planned, including:

  • Studies in children under 12 years old with hemophilia[6]
  • Long-term safety and efficacy studies lasting up to 6 years[2]
  • Post-marketing surveillance studies to monitor the safety of concizumab once it becomes commercially available[1]

These ongoing studies will help researchers and healthcare providers better understand how concizumab can be used to improve the lives of people with hemophilia.

Aspect Details
Drug Name Concizumab (also known as Alhemo in some trials)
Conditions Studied Hemophilia A and B, with and without inhibitors
Administration Daily subcutaneous injection
Dosing Typically starting at 0.15-0.20 mg/kg, with potential adjustments up to 0.25 mg/kg
Primary Outcomes Number of treated bleeding episodes
Key Secondary Outcomes Safety, antibody development, pharmacokinetics, pharmacodynamics
Trial Durations Ranging from 24 weeks to several years
Trial Phases Phase 2 and Phase 3 studies, plus post-marketing surveillance
Geographic Regions Global trials including Asia, Europe, North America, and Africa

FAQ

  • What is Concizumab? Concizumab is an investigational drug being studied as a treatment for hemophilia A and B, with and without inhibitors. It is administered as a daily subcutaneous (under the skin) injection to help prevent bleeding episodes.
  • How does Concizumab work? Concizumab works by inhibiting tissue factor pathway inhibitor (TFPI), which helps promote blood clotting. By blocking TFPI, Concizumab aims to improve blood clotting in people with hemophilia.
  • What types of hemophilia is Concizumab being studied for? Clinical trials are investigating Concizumab for hemophilia A and B, both with and without inhibitors. This includes severe forms of these conditions.
  • How is Concizumab administered in the clinical trials? In the trials, Concizumab is typically administered as a daily subcutaneous injection. The dose may be adjusted based on individual patient response and monitored blood levels of the drug.
  • What are the main outcomes being measured in the Concizumab trials? The key outcomes being assessed include the number of bleeding episodes, safety (including adverse events), development of antibodies to Concizumab, and various blood clotting parameters like thrombin generation and TFPI levels.

Ongoing Clinical Trials on Concizumab

  • Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Greece Italy Lithuania Norway +4

  • Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors

    Not recruiting

    1 1 1
    Investigated drugs:
    Croatia Denmark France Italy Poland Portugal +2

  • Study on How Concizumab Works for Patients with Hemophilia A or B Without Inhibitors

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark Estonia France Germany Hungary Italy +5

Glossary

  • Hemophilia: A rare genetic bleeding disorder where the blood doesn't clot properly due to a lack of blood-clotting proteins (clotting factors).
  • Inhibitors: Antibodies that the immune system develops against clotting factor treatments in some people with hemophilia, making these treatments less effective.
  • Prophylaxis: Preventive treatment given regularly to stop bleeding episodes before they occur.
  • Subcutaneous: Underneath the skin. Concizumab is injected into the fatty tissue just beneath the skin.
  • Tissue Factor Pathway Inhibitor (TFPI): A protein that regulates blood clotting by inhibiting certain steps in the clotting process.
  • Thrombin: An enzyme in blood plasma that causes the clotting of blood by converting fibrinogen to fibrin.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body.
  • Adverse Event: Any undesirable experience associated with the use of a medical product in a patient.
  • Bleeding Episode: An instance of uncontrolled bleeding in a person with hemophilia, which may be spontaneous or caused by injury.

References

  1. https://clinicaltrials.gov/study/NCT06285071
  2. https://clinicaltrials.gov/study/NCT04083781
  3. https://clinicaltrials.gov/study/NCT03196284
  4. https://clinicaltrials.gov/study/NCT04082429
  5. https://clinicaltrials.gov/study/NCT03196297
  6. https://clinicaltrials.gov/study/NCT05135559